Lensmar C, Prieto J, Dahlén B, Eklund A, Grunewald J, Roquet A
Department of Medicine, Division of Respiratory Medicine, Karolinska Hospital and Karolinska Institutet, Stockholm, Sweden.
Clin Exp Allergy. 1999 Dec;29(12):1632-40. doi: 10.1046/j.1365-2222.1999.00757.x.
The alveolar macrophage (AM) constitutes an important link between pulmonary innate and adaptive immunity due to its antigen-presenting capacity and ability to express different immunomodulating mediators. The role of AMs in the pathogenesis of allergic inflammation has yet to be fully determined.
To investigate clinical effects and any change in the AM phenotype pattern after inhalation of sub-clinical doses of allergen by asthmatic patients.
Eight subjects with allergic asthma underwent repeated low-dose allergen provocations equivalent to 10% of PD20. AMs recovered with bronchoalveolar lavage (BAL) were characterized by flow cytometric analysis of adhesion molecules, co-stimulatory molecules and markers for AM population activation and heterogeneity.
An allergic airway inflammation, sub-clinical in six out of eight subjects, was obtained after low-dose allergen provocations, as determined by increased airway methacholine reactivity, increased BAL fluid total cell and eosinophil counts and increased serum ECP levels. The AMs showed a post-challenge altered phenotype pattern with a decreased expression of CD11a, CD16, CD71 and HLA class I and an increased expression of CD11b and CD14. The AMs were positive for CD83 and a weak post-challenge increase in the CD83 expression was found.
Repeated low-dose allergen exposure induces an allergic airway inflammation in asthmatic subjects. The inflammation is associated with an altered AM phenotype pattern, consistent with an influx of monocytes and a hypothetical increased accessory cell function in the airways, possibly contributing to the development and sustenance of airway inflammation in asthma.
肺泡巨噬细胞(AM)由于其抗原呈递能力和表达不同免疫调节介质的能力,构成了肺部固有免疫和适应性免疫之间的重要联系。AMs在过敏性炎症发病机制中的作用尚未完全确定。
研究哮喘患者吸入亚临床剂量变应原后AMs表型模式的变化及临床效果。
8名过敏性哮喘患者接受相当于PD20 10%的重复低剂量变应原激发试验。通过对支气管肺泡灌洗(BAL)回收的AMs进行粘附分子、共刺激分子以及AMs群体活化和异质性标志物的流式细胞术分析来进行表征。
低剂量变应原激发试验后,8名受试者中有6名出现了亚临床过敏性气道炎症,这通过气道乙酰甲胆碱反应性增加、BAL液总细胞和嗜酸性粒细胞计数增加以及血清ECP水平升高得以确定。AMs在激发试验后显示出表型模式改变,CD11a、CD16、CD71和HLA I类分子表达降低,而CD11b和CD14表达增加。AMs的CD83呈阳性,且激发试验后CD83表达有微弱增加。
重复低剂量变应原暴露可诱导哮喘患者出现过敏性气道炎症。这种炎症与AMs表型模式改变有关,这与单核细胞流入以及气道中假设的辅助细胞功能增加一致,可能有助于哮喘气道炎症的发生和持续。